430 reports of this reaction
3.7% of all CABOTEGRAVIR reports
#4 most reported adverse reaction
VIRAL LOAD INCREASED is the #4 most commonly reported adverse reaction for CABOTEGRAVIR, manufactured by ViiV Healthcare Company. There are 430 FDA adverse event reports linking CABOTEGRAVIR to VIRAL LOAD INCREASED. This represents approximately 3.7% of all 11,616 adverse event reports for this drug.
Patients taking CABOTEGRAVIR who experience viral load increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VIRAL LOAD INCREASED is moderately reported among CABOTEGRAVIR users, representing a notable but not dominant share of adverse events.
In addition to viral load increased, the following adverse reactions have been reported for CABOTEGRAVIR:
The following drugs have also been linked to viral load increased in FDA adverse event reports:
VIRAL LOAD INCREASED has been reported as an adverse event in 430 FDA reports for CABOTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
VIRAL LOAD INCREASED accounts for approximately 3.7% of all adverse event reports for CABOTEGRAVIR, making it a notable side effect.
If you experience viral load increased while taking CABOTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.